Herceptin and Multiple sclerosis - a phase IV clinical study of FDA data

Summary:

Multiple sclerosis is reported as a side effect among people who take Herceptin (trastuzumab), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Perjeta, and have Breast cancer female.

The phase IV clinical study analyzes which people have Multiple sclerosis when taking Herceptin. It is created by eHealthMe based on reports of 41,859 people who have side effects when taking Herceptin from the FDA, and is updated regularly.

What is Herceptin?

Herceptin has active ingredients of trastuzumab. It is often used in breast cancer. eHealthMe is studying from 42,205 Herceptin users. Check the latest studies of Herceptin.

What is Multiple sclerosis?

Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,088 drugs and 1,360 conditions by eHealthMe. Check the latest studies of Multiple sclerosis.

On Jul, 11, 2026

41,859 people reported to have side effects when taking Herceptin.
Among them, 22 people (0.05%) have Multiple sclerosis.

Could Herceptin cause Multiple sclerosis?

Among these 22 people:

How long have people been on Herceptin when they have Multiple sclerosis? *

What is the gender of people who have Multiple sclerosis when taking Herceptin? *

female: 100 %
male: 0.0 %

What is the age of people who have Multiple sclerosis when taking Herceptin? *

What are other drugs people take besides Herceptin? *

What are other side effects people have besides Multiple sclerosis? *

Fatigue (feeling of tiredness): 7 people, 31.82%
Diarrhea: 4 people, 18.18%
Joint Pain: 3 people, 13.64%
Insomnia (sleeplessness): 3 people, 13.64%
Urinary Tract Infection: 3 people, 13.64%
Neuropathy Peripheral (surface nerve damage): 3 people, 13.64%
Dry Skin: 3 people, 13.64%
Drug Exposure During Pregnancy: 3 people, 13.64%
Constipation: 3 people, 13.64%
Pollakiuria (abnormally frequent passage of relatively small quantities or urine): 2 people, 9.09%

What are the existing conditions these people have? *

Breast Cancer Female: 3 people, 13.64%
Metastases To Lymph Nodes (cancer spreads to lymph node): 2 people, 9.09%
Inflammatory Carcinoma Of The Breast: 2 people, 9.09%
Tremor (trembling or shaking movements in one or more parts of your body): 1 person, 4.55%
Stress And Anxiety: 1 person, 4.55%
Sleep Disorder: 1 person, 4.55%
Muscle Spasms (muscle contraction): 1 person, 4.55%
Metastases To Bone (cancer spreads to bone): 1 person, 4.55%
Bipolar Disorder (mood disorder): 1 person, 4.55%
Affective Disorder (mental disorder): 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Herceptin and have Multiple sclerosis?

- Check whether Multiple sclerosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Herceptin:

Herceptin (42,205 reports)

Browse all side effects of Herceptin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Multiple sclerosis:

Multiple sclerosis (1,088 drugs)

Browse all the conditions that are associated with Multiple sclerosis:

Multiple sclerosis (1,360 conditions)

Related publications that referenced our studies

Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Saleh M, Bourcier T, Noel G, Speeg-Schatz C, Gaucher D, "Bilateral macular ischemia and severe visual loss following trastuzumab therapy", Acta Oncologica, 2011 Apr .
Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Saleh M, Bourcier T, Noel G, Speeg-Schatz C, Gaucher D, "Bilateral macular ischemia and severe visual loss following trastuzumab therapy", Acta Oncologica, 2011 Apr .

How the study uses the data?

The study uses data from the FDA. It is based on trastuzumab (the active ingredients of Herceptin) and Herceptin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.